Kotinin

Kotinin
IUPAC ime
	(5S)-1-metil-5-(3-piridil)pirolidin-2-on
Klinički podaci
Način primene	Oralno, pušenjem
Pravni status
Pravni status	℞ (Prescription only);
Farmakokinetički podaci
Poluvreme eliminacije	20 sata
Identifikatori
CAS broj	486-56-6
ATC kod	none
PubChem	CID 854019
ChemSpider	746405
UNII	K5161X06LL
ChEMBL	CHEMBL578211
Hemijski podaci
Formula	C10H12N2O
Molarna masa	176,22 g/mol
	SMILES O=C2N(C)[C@H](c1cnccc1)CC2; ;
	InChI InChI=1S/C10H12N2O/c1-12-9(4-5-10(12)13)8-3-2-6-11-7-8/h2-3,6-7,9H,4-5H2,1H3/t9-/m0/s1 ; Key:UIKROCXWUNQSPJ-VIFPVBQESA-N ;

Kotinin je alkaloid prisutan u duvanu i kao metabolit nikotina.^[1]^[2] Reč "kotinin" je anagram "nikotina". Kotinin se koristi kao biomarker za izlaganje duvanskom dimu. On je u prodaji kao antidepresiv pod imenom Scotine.^[1]

Slično nikotinu, kotinin se vezuje za, aktivira, i desenzituje neuronski nikotinske acetilholinske receptore, mada sa znatno nižom potentnošću.^[2]^[3]^[4]^[5] On ispoljava nootropne i antipsihoticima slične efekte.^[6]^[7]

Reference уреди

^ ^а ^б Triggle, David J. (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9.
^ ^а ^б Dwoskin LP, Teng L, Buxton ST, Crooks PA (1999). „(S)-(-)-Cotinine, the major brain metabolite of nicotine, stimulates nicotinic receptors to evoke [3H]dopamine release from rat striatal slices in a calcium-dependent manner”. The Journal of Pharmacology and Experimental Therapeutics. 288 (3): 905—11. PMID 10027825.
^ Anderson DJ, Arneric SP (1994). „Nicotinic receptor binding of [3H]cytisine, [3H]nicotine and [3H]methylcarbamylcholine in rat brain”. European Journal of Pharmacology. 253 (3): 261—7. PMID 8200419. doi:10.1016/0014-2999(94)90200-3.
^ Briggs CA, McKenna DG (1998). „Activation and inhibition of the human alpha7 nicotinic acetylcholine receptor by agonists”. Neuropharmacology. 37 (9): 1095—102. PMID 9833639. doi:10.1016/S0028-3908(98)00110-5.
^ Buccafusco JJ, Shuster LC, Terry AV (2007). „Disconnection between activation and desensitization of autonomic nicotinic receptors by nicotine and cotinine”. Neuroscience Letters. 413 (1): 68—71. PMID 17157984. doi:10.1016/j.neulet.2006.11.028.
^ Buccafusco JJ, Terry AV (2009). „A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists”. Biochemical Pharmacology. 78 (7): 852—62. PMID 19577545. doi:10.1016/j.bcp.2009.06.102.
^ Buccafusco JJ, Beach JW, Terry AV (2009). „Desensitization of nicotinic acetylcholine receptors as a strategy for drug development”. The Journal of Pharmacology and Experimental Therapeutics. 328 (2): 364—70. PMC 2682277  . PMID 19023041. doi:10.1124/jpet.108.145292.

Literatura уреди

Spoljašnje veze уреди

[isbn0-412-46630-9-1] а ^б Triggle, David J. (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9.

[pmid10027825-2] а ^б Dwoskin LP, Teng L, Buxton ST, Crooks PA (1999). „(S)-(-)-Cotinine, the major brain metabolite of nicotine, stimulates nicotinic receptors to evoke [3H]dopamine release from rat striatal slices in a calcium-dependent manner”. The Journal of Pharmacology and Experimental Therapeutics. 288 (3): 905—11. PMID 10027825.

[pmid8200419-3] Anderson DJ, Arneric SP (1994). „Nicotinic receptor binding of [3H]cytisine, [3H]nicotine and [3H]methylcarbamylcholine in rat brain”. European Journal of Pharmacology. 253 (3): 261—7. PMID 8200419. doi:10.1016/0014-2999(94)90200-3.

[pmid9833639-4] Briggs CA, McKenna DG (1998). „Activation and inhibition of the human alpha7 nicotinic acetylcholine receptor by agonists”. Neuropharmacology. 37 (9): 1095—102. PMID 9833639. doi:10.1016/S0028-3908(98)00110-5.

[pmid17157984-5] Buccafusco JJ, Shuster LC, Terry AV (2007). „Disconnection between activation and desensitization of autonomic nicotinic receptors by nicotine and cotinine”. Neuroscience Letters. 413 (1): 68—71. PMID 17157984. doi:10.1016/j.neulet.2006.11.028.

[pmid19577545-6] Buccafusco JJ, Terry AV (2009). „A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists”. Biochemical Pharmacology. 78 (7): 852—62. PMID 19577545. doi:10.1016/j.bcp.2009.06.102.

[pmid19023041-7] Buccafusco JJ, Beach JW, Terry AV (2009). „Desensitization of nicotinic acetylcholine receptors as a strategy for drug development”. The Journal of Pharmacology and Experimental Therapeutics. 328 (2): 364—70. PMC 2682277  . PMID 19023041. doi:10.1124/jpet.108.145292.

[1]

[2]

[3]

[4]

[5]

[6]

[7]